NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Aurora Cannabis Inc. (ACB) Stock Analysis

Aurora Cannabis Inc. (ACB) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACB

$3.96

−$0.01 (−0.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACB with… →

ACB Key Statistics

As of Oct 21, 2026
Trading
Open
$3.98
Previous Close
$3.97
Day's Range
3.92–4.09
52-Week Range
2.56–6.36
Volume
788.29K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$250.71M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.61
Financials (FY)
Revenue (FY)
$320.59M+10.97%
Net Income (FY)
−$135.96M−8,645.82%
Profit marginThe share of revenue left as profit after all costs and taxes.
−38.25%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.31M
1-Year Return
−22.96%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.32M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACB closed at $3.96, −22.96% over 1 year.

Aurora Cannabis Inc. (ACB) has a market capitalization of $250.71M.

In fiscal 2025, ACB reported revenue of $320.59M.

ACB Stock Return by Calendar Year

Aurora Cannabis Inc. (ACB) 10-year return: what $10,000 became

1 year
$10,000 $7,704
−22.96%
5 years
$10,000 $537
−94.63%
10 years
$10,000 $204
−97.96%

If you had invested $10,000 in Aurora Cannabis Inc. (ACB) 10 years ago, at the close on October 21, 2016, it would have been worth $204 at the close on October 21, 2026: −97.96% in total, −32.26% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.16%
2025−0.71%
2024−10.71%
2023−48.43%
2022−82.94%
2021−34.90%
2020−67.94%
2019−56.45%
2018−32.59%
2017+343.60%
2016 (partial year)+262.11%

As of October 21, 2026.

ACB Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$320.59M−$135.96M−42.4%
2024$288.91M$1.59M0.6%
2023$269.64M−$69.33M−25.7%
2022$221.34M−$1.72B−776.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$320.59M$136.65M−$46.66M−$135.96M−42.4%
2024$288.91M$180.95M$10.43M$1.59M0.6%
2023$269.64M$131.73M−$31.05M−$69.33M−25.7%
2022$221.34M$21.23M−$219.38M−$1.72B−776.0%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

ACB Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricACBDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.802.1062% below
Profit margin−38.25%−8.14%30.1 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aurora Cannabis Inc. (ACB) carries a market capitalisation of $250.71M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 1,028.

Over the past 52 weeks the price has ranged from $2.56 to $6.36. The most recent close on file for ACB is $3.96, dated October 21, 2026. That is −$0.01 (−0.25%) against the previous close. The latest close sits 54.69% above that 52-week low.

Financial Health

In fiscal 2025, Aurora Cannabis Inc. reported revenue of $320.59M. Against the prior fiscal year total of $288.91M, that is a change of +10.97%. The same year closed with a net loss of $135.96M. Profit margin runs at −38.25%. That is 30.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.61.

Across the 4 fiscal years on file, revenue moves from $221.34M in 2022 to $320.59M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.8. On price-to-sales that is 61.99% below the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is −22.96%. Measured over 10 years, that is −32.26% a year compounded. The reported beta is 1.42. Annualized volatility over the trailing 10 years is 96.46%.

Growth & Income

No dividend is on file for ACB.

Across the complete calendar years on file, 2017 returned +343.60% and 2022 returned −82.94%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −6.16%.

Peer Comparison

Aurora Cannabis Inc. (ACB) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aurora Cannabis Inc. ACB $250.71M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Aurora Cannabis Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aurora Cannabis Inc.

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis products in Canada and internationally. The company offers pharmaceutical-grade cannabis products; and medical and consumer cannabis products. It also provides harvested cannabis, trim, cannabis oils, capsules, edibles, vaporizers, dried and fresh cannabis, cannabis plants, cannabis seeds, edible cannabis, cannabis extracts, flowers, vapes / inhalable extracts, edibles / pastilles, concentrates, and cannabis topicals; and patient counseling and outreach services. Its brand portfolio includes Aurora, Being, CanniMed, CraftPlant, Daily Special, Drift, Greybeard, IndiMed, MedReleaf, Pedanios, San Raf, Tasty's, Whistler, and WMMC. The company also engages in pharmacy activities. Aurora Cannabis Inc. was founded in 2013 and is headquartered in Edmonton, Canada.

Visit website →